"We provide knowledge and information about CGMP and Quality Systems to the Life Science industry"
May 17, 2017 | Industry: General information / Consulting
Key2Compliance AB has started a collaboration with Symbioteq Kvalitet AB during spring 2017, where Symbioteq will work more actively to strengthen our range of training within Medtech and several of Symbioteq's consultants will reinforce as trainers.
Symbioteq will no longer organize training courses and will focus entirely on consulting and broadening its range of consulting services from Medtech to Pharmaceuticals and the entire Life Science sector.
"We are convinced that cooperation will ensure that customers’ need are met even better for quality support and quality education and training through greater accessibility to a wide range of services in the area," said Key2Compliance® chairman Anna Lundén.
As part of the company's long-term strategy to become Northern Europe's premium suppliers of specialist services in quality assurance and regulations for the pharmaceutical and medical device industry, Symbioteq Kvalitet AB has also acquired shares in Key2Compliance AB.
The new rules significantly tighten the controls to ensure that medical devices are safe and effective and at the same time foster innovation and improve the competitiveness of the medical device sector. The new rules also better reflect the most recent scientific and technological progress and set the gold standard for medical device regulation globally. The revised rules also provide the conditions needed to consolidate the role of the EU in the long-term as a global leader in the sector.
March 13, 2017 | Industry: Pharmaceuticals
and Medical Device
In this interesting article David Churchward reflects on the international data integrity workshops in China in October 2016. During the workshops, regulators discussed their findings from inspections where breaches in data integrity had been identified. Issues relating to pressure, motivation, and ultimate disconnection between front line employees and their managers were hot topics; and the inspectorate blog provides an opportunity to share some of this experience.
January 12, 2017 | Industry: Pharmaceuticals
and Medical Device
The draft document was issued January 2015 and is now published as final. This guidance describes and explains the final rule on current good manufacturing requirements for combination products (21CFR4) that FDA issued on January 22, 2013.
New article from James Vesper and Keven O’Donnell published in Pharmaceutical Engineering, Nov-Dec 2016.
From the content:
"The intent of QRM is to make data-driven and scientifically sound decisions proactively, not to justify an action or a decision that has already been taken"
"Formal risk assessments sometimes fail to add value or clarity to a situation because risk assessments often only superficially address root cause analysis, resulting in ineffective risk-control actions"
"Some firms have not yet seen that hazard identification and risk assessment tools can be used together synergistically"